Your browser is no longer supported. Please, upgrade your browser.
Yumanity Therapeutics, Inc.
Index- P/E- EPS (ttm)-14.09 Insider Own0.60% Shs Outstand10.30M Perf Week-4.09%
Market Cap42.96M Forward P/E- EPS next Y-4.56 Insider Trans0.00% Shs Float8.93M Perf Month-51.55%
Income-52.90M PEG- EPS next Q-1.02 Inst Own36.20% Short Float1.17% Perf Quarter-58.13%
Sales14.20M P/S3.03 EPS this Y6.70% Inst Trans-14.32% Short Ratio0.50 Perf Half Y-72.56%
Book/sh3.15 P/B1.34 EPS next Y-38.50% ROA- Target Price27.67 Perf Year-79.90%
Cash/sh4.56 P/C0.93 EPS next 5Y- ROE- 52W Range4.18 - 26.20 Perf YTD-75.18%
Dividend- P/FCF- EPS past 5Y2.40% ROI-76.60% 52W High-83.89% Beta0.39
Dividend %- Quick Ratio2.70 Sales past 5Y9.80% Gross Margin- 52W Low0.96% ATR0.50
Employees46 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)16.94 Volatility6.89% 7.63%
OptionableYes Debt/Eq0.45 EPS Q/Q69.10% Profit Margin- Rel Volume1.27 Prev Close4.38
ShortableYes LT Debt/Eq0.27 Earnings- Payout- Avg Volume210.00K Price4.22
Recom1.70 SMA20-37.18% SMA50-50.42% SMA200-67.06% Volume266,270 Change-3.65%
Nov-16-21 04:30PM  
Nov-15-21 07:30AM  
Nov-12-21 04:05PM  
Nov-10-21 07:00AM  
Oct-14-21 07:00AM  
Sep-09-21 04:15PM  
Aug-16-21 07:00AM  
Aug-12-21 04:15PM  
Aug-06-21 07:00AM  
Jun-14-21 07:00AM  
May-27-21 07:00AM  
May-17-21 04:05PM  
May-13-21 07:00AM  
May-12-21 08:00AM  
May-04-21 08:00AM  
Apr-28-21 08:07PM  
Apr-22-21 07:00AM  
Apr-13-21 08:00AM  
Apr-06-21 08:00AM  
Mar-31-21 08:48AM  
Mar-23-21 09:41AM  
Mar-09-21 08:00AM  
Mar-02-21 04:05PM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.